Drugs / DF-003
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06395285 | May 2025 → Jul 2026 overdue | retinal dystrophy, optic nerve edema, splenomegaly, anhidrosis, and migraine headache syndrome | Shanghai Yao Yuan Biotechnology Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT05997641 | Sep 2023 → Oct 2026 expected | — | Shanghai Yao Yuan Biotechnology Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DF-003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06395285 ↗ |
| Known as | LP-DF003 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1606347 ↗ |
| Known as | Rp 8br-pet-cgmps | ChEMBL registry synonym — accepted as the source's own label CHEMBL1606347 ↗ |
| Action | Inhibit | “inhibitor of alpha-kinase 1 (ALPK1)” NCT05997641 ↗ |
| Modality | Small molecule | “potent small molecule inhibitor” NCT05997641 ↗ |
| Route | Oral | “Oral administration by capsules” NCT05997641 ↗ |
| Target | ALPK1 | “inhibitor of alpha-kinase 1 (ALPK1)” NCT05997641 ↗ |